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a  b  s  t  r  a  c  t
A follow-up  study  was  conducted  to determine  the  magnitude  of  and  factors  related  to
adherence  to  artemether/lumefantrine  (ALu)  treatment  in  rural  settings  in  Tanzania.  Chil-
dren  in ﬁve  villages  of  Kilosa  District  treated  at health  facilities  were  followed-up  at their
homes on Day  7 after  the  ﬁrst  dose  of ALu.  For  those  found  to  be positive  using  a  rapid
diagnostic  test  for  malaria  and  treated  with  ALu,  their caretakers  were  interviewed  on  drug
administration  habits.  In addition,  capillary  blood  samples  were  collected  on  Day  7 to  deter-
mine lumefantrine  concentrations.  The  majority  of  children  (392/444;  88.3%)  were  reported
to have  received  all doses,  in  time.  Non-adherence  was  due  to untimeliness  rather  than
missing  doses  and  was highest  for the last  two  doses.  No  signiﬁcant  difference  was  found
between  blood  lumefantrine  concentrations  among  adherent  (median  286  nmol/l)  and non-
adherent  [median  261  nmol/l;  range  25  nmol/l  (limit  of  quantiﬁcation)  to 9318  nmol/l].
Children  from  less  poor households  were  more  likely  to adhere  to  therapy  than  the  poor
[odds ratio (OR)  = 2.45,  95%  CI 1.35–4.45;  adjusted  OR = 2.23,  95%  CI 1.20–4.13].  The  high
reported  rate  of  adherence  to ALu  in rural  areas  is  encouraging  and  needs  to  be  preserved
to reduce  the  risk  of  emergence  of  resistant  strains.  The  age-based  dosage  schedule  and
lack of  adherence  to ALu treatment  guidelines  by  health  facility  staff may  explain  both
the  huge variability  in  observed  lumefantrine  concentrations  and  the  lack  of difference  in
concentrations  between  the  two groups.
© 2011 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd.
 All rights reserved.
1. Introduction
In 2006, Tanzania switched from sulfadoxine/
pyrimethamine (SP) to artemether/lumefantrine (ALu) as
∗ Corresponding author. Present address: P.O. Box 65015, Dar es
Salaam, Tanzania. Tel.: +255 22 215 0304/5; fax: +255 22 215 3114.
E-mail addresses: dsimba@muhas.ac.tz, daudisimba@yahoo.com
(D.O. Simba).
the ﬁrst-line treatment recommended for uncompli-
cated falciparum malaria. The limited availability of
ALu, combined with its rapid onset of action and rapid
clearance of severe clinical symptoms, might tempt
caretakers to discontinue treatment prematurely1 and
to keep the remaining medicine for an ‘anticipated’ next
attack.2 This may  accelerate the pace of development
of drug resistance,3 thus making it important to main-
tain high adherence rates to preserve the efﬁcacy of
0035-9203/$ – see front matter ©  2011 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.
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artemisinin-based combination therapy (ACT) in Africa
and elsewhere.4
Adherence levels as high as 90% have been reported in
controlled clinical trials.5,6 These ﬁgures are likely to be
an overestimation because in real-life situations caretakers
are neither given detailed instruction on to how to admin-
ister the treatment nor do they receive follow-up on the
use of the drugs by the child.
Two community-based Tanzanian studies conducted
in Kilombero/Ulanga Districts and Zanzibar Islands did
report high levels of adherence to ACT treatment regimens
(77% and 99%, respectively).7,8 However, more informa-
tion on adherence to ALu is required in order to inform
the implementation of drug policy change, given the low
access to ALu in rural remote areas.9 Community-based
data collected under real-life settings are also required in
order to estimate the level of community effectiveness,10,11
which reﬂects the success of implementation of a drug pol-
icy change.
Several factors have been reported to inﬂuence adher-
ence to treatment, including: education of caretakers and
the use of pre-packaged co-blister packets12,13; drug efﬁ-
cacy and rapid improvement of symptoms1,3,14; local
perceptions about the disease15; and caretakers perceiv-
ing a child playing after a single dose as a sign of cure.16
Most of these ﬁndings, however, are based on studies per-
formed in Asia or during the time when chloroquine (CQ)
and SP were the ﬁrst-line recommended drugs.7,8 This
community-based study was therefore conducted to deter-
mine the level of and factors inﬂuencing adherence to ALu
among under-ﬁves in a real-life situation in rural Tanzania.
Information from this study will be important in design-
ing appropriate implementation programmes for ACT in
Tanzania and elsewhere in Africa.5
2. Materials and methods
2.1. Study site
A 12-month follow-up study was conducted in June
2008 in Kilosa District, Tanzania. A detailed description of
the district is reported elsewhere.9 Malaria accounts for
more than one-half of clinical presentations by patients
attending the outpatient clinics and 60% of deaths among
under-ﬁve hospital admissions (district annual report,
2008). The health facilities are organised at three levels,
with 61 dispensaries that are at the lowest contact level,
seven health centres at the middle, and two hospitals as
well as a district hospital at the highest level. Only hospi-
tals and health centres have a functioning microscope for
malaria diagnosis. Dispensaries have a catchment popula-
tion of approximately 10 000 people, manned by a clinician
and a public health nurse, and serve the majority of the
children suspected to have uncomplicated malaria.
2.2. Study design and sample size
This was a follow-up observational study. Stratiﬁed
cluster sampling was carried out. All 30 rural villages listed
as rural in the National Census Report, 2003, located in
the wet-lowland areas, were grouped into those with and
without a health facility. One village among 12 villages with
a health facility and two  villages among 18 villages without
a health facility were randomly selected using EPI Info v.6
(CDC, Atlanta, GA, USA). The rationale of 1:2 was based on
the proportion of villages with health facilities in the dis-
trict. During the course of data collection, it was  necessary
to compare between rural and semi-urban villages. Thus,
the ward headquarters of the three rural villages located
in semi-urban areas were included in the study. Two of
the initial villages shared the same ward; therefore, two
semi-urban villages were added making the total number
of study villages equal to ﬁve (Figure 1).
The unadjusted sample size was calculated as 280 based
on the assumption that 24% of caretakers would adhere to
treatment, as reported in a study in Uganda.11 Although
this study was based on CQ treatment, this was the most
recent adherence study in a setting similar to Tanzania.
A maximum 95% CI of ±5% was  required, and adding
10% for possible loss to follow-up and another 27% as a
correction factor for clustering effect (intracluster correla-
tion coefﬁcient = 0.01), the sample size was  calculated as
391, approximated to 400. Based on Tanzanian studies, it
was  assumed that approximately 80–90%17,18 of children
with fever would be treated at health centres or dispen-
saries. Data collection was  planned to be completed in a
4-month period. However, during the study it was  found
that most caretakers residing in villages without a health
facility sought care from drug vendors and ordinary shops
instead.9 Consequently, it took 12 months to recruit the
required sample size.
2.3. Data collection
Three research assistants (RA) were purposely recruited
both to administer the questionnaire and to take blood
samples. They were taught for 6 days on how to administer
the questionnaire and take blood samples.
At the time of the study, there were only three health
facilities in the study area that provided ALu, all of which
were public facilities. Therefore, these health facilities
acted as enrolment centres where RAs identiﬁed the names
of children who  met  the enrolment criteria from the labo-
ratory and outpatient registers.
The enrolment criteria of children for the study were:
• child aged 3–59 months;
• child diagnosed at the health facility as positive for
malaria using a rapid diagnostic test (RDT);
• child prescribed with the correct dose of ALu according to
national treatment guideline, which is based on weight
and age, twice daily for 3 days19; and
• child resided in one of the ﬁve selected villages.
RAs traced the children home on Day 7 after the ﬁrst
dose of ALu. Recruitment of children into the study was
performed after a caretaker had provided written informed
consent. Caretakers were not given prior information about
the follow-up. Caretakers were interviewed regarding the
instructions received at the facility, the day and time they
administered the drugs, whether food was  taken with the
drugs, whether food was  cooked with oil, and whether
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Figure 1. Overview of the process to recruit 5 out of 161 villages and study subjects (n = 446) in Kilosa District, Tanzania.
the child vomited, and if so, how soon after the drug
intake. (The questionnaire can be obtained from the corre-
sponding author upon request.) Two caretakers could not
remember the events and were excluded from the analysis.
In addition, baseline data on demographic and socioeco-
nomic status (SES) and knowledge about malaria treatment
were obtained. The questionnaire was based on a literature
review of previous adherence studies.6,11 A pilot study was
carried out for 1 week in two villages to validate the ques-
tionnaire and to gain ﬁeld experiences in blood sampling
techniques.
2.3.1. Deﬁnition of adherence to
artemether/lumefantrine treatment schedule
Adherence to treatment with ALu was deﬁned as a care-
taker reported to have administered two doses daily for 3
days; if the ﬁrst dose was started in the evening, then one
dose on the ﬁrst day, two doses for 2 days and the last dose
on the fourth day, in the morning. The dose was one tablet
of ALu (20 mg  artemether and 120 mg  lumefantrine) for a
child aged <3 years and two tablets (artemether 40 mg  and
lumefantrine 240 mg)  for a child aged ≥3 years.
2.4. Blood sampling, handling and drug sample analysis
RAs collected capillary blood samples from the chil-
dren on Day 7 through a ﬁnger-prick using the method
previously described by Ntale et al.20 After drying the ﬁl-
ter paper, the specimen was stored in a plastic envelope
to avoid contamination and was collected by the super-
visors weekly. Filter paper samples were stored at room
temperature for 3–15 months at the Pharmacology Labo-
ratory of Muhimbili University (Dar es Salaam, Tanzania)
before transfer to the Clinical Pharmacology Laboratory
at Karolinska Institutet (Stockholm, Sweden) where blood
lumefantrine concentrations were determined by HPLC as
described by Ntale et al.20 Samples were assayed with an
intra-assay and inter-assay coefﬁcient of variation of <9.2%
and with a limit of quantiﬁcation (LoQ) of 25 nmol/l.
At the time of the study, several pilot studies were ongo-
ing in the country aimed at rolling out of RDTs for malaria.
We therefore introduced RDTs for malaria diagnosis in the
three facilities, since Kilosa was  not one of the pilot dis-
tricts. Health workers in each facility and village health
workers in two dispensaries that were understaffed were
trained in performing the RDT for malaria. A 1-day training
course was held followed by 2 days of work under super-
vision. The tests were performed routinely for all children
under ﬁve with a suspected malaria diagnosis irrespective
of whether they resided in the ﬁve study villages or not.
The RDT called Paracheck (Orchid Biomedical Systems, Goa,
India) was obtained through donation from the National
Malaria Control Programme.
2.5. Data analysis
Data were double-entered into EpiData 3.0 (EpiData
Association, Odense, Denmark) before being transferred to
Stata v.10.1 (StataCorp., College station, TX, USA). Bivariate
analysis was  performed on variables thought to inﬂuence
adherence to treatment with ALu. Variables found to be
associated were introduced in a stepwise multiple regres-
sion model using a cut-off point of 0.10. The variables were:
knowledge of treatment of severe malaria; SES; and intake
of food with oil. Marital status and age of the child were
also included. The variables SES and intake of food with oil
remained in the ﬁnal regression model; these were tested
for interaction and no association was found. SES was
calculated using principal component analysis in which
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Table 1
Background demographic characteristics of children under ﬁve enrolled in the study and their caretakers by reported adherence status (n = 444)
Characteristic of parent or child Reported non-adherence Reported adherence Total P-value
n  (%) n (%)
Caretaker’s age (years)
<30 32 (12.3) 228 (87.7) 260 0.642
≥30 20 (10.9) 164 (89.1) 184
Child’s age (years)
<2 26 (14.1) 159 (85.9) 185 0.195
≥2  26 (10.0) 233 (90.0) 259
Child’s sex
Male 30 (13.7) 189 (86.3) 219 0.199
Female  22 (9.8) 203 (90.2) 225
Caretaker’s marital status
Not married 34 (14.3) 204 (85.7) 238 0.070
Married 18 (8.7) 188 (91.3) 206
Caretaker’s education (years)
<7 25 (13.4) 162 (86.6) 187 0.354
≥7  27 (10.5) 230 (89.5) 257
Residence
Rural 40 (12.5) 281 (87.5) 321 0.428
Semi-urban 12 (9.8) 111 (90.2) 123
Village status
Without a health facility 22 (13.0) 147 (87.0) 169 0.502
With  a health facility 30 (10.9) 245 (89.1) 275
Overall 52 (11.7) 392 (88.3) 444
19 assets adopted from the Tanzania Demographic Health
Survey were used.21 Variables that had ≥90% of the study
children in one category were excluded. The ﬁnal list
included household construction material composing walls
and the roof; the source of drinking water and type of light;
and ownership of a watch or clock, radio, mattress, a bed-
net and a bicycle. The ﬁrst component explained 30% of
the variability and was used to construct a SES index. The
SES index was categorised in ﬁve quintiles, and households
in the ﬁrst and second quintiles were classiﬁed as poor and
the others as less poor. Crude and adjusted odds ratios (OR)
with 95% CIs were reported.
Blood lumefantrine concentrations were found to have a
positive skewed distribution. Hence, log-transformed val-
ues of lumefantrine concentrations were used for statistical
testing of difference in mean levels (t-test) between chil-
dren who adhered to therapy and those who did not. The
original concentration levels were also described using
medians and box plot. Before and after comparison of blood
lumefantrine concentrations could not be done because
this was an observational study that aimed at determin-
ing adherence to ALu under real-life conditions. Blood
sampling for determination of lumefantrine concentrations
was not done routinely at the health facilities. Permission to
conduct the study was obtained from the regional and dis-
trict authorities. Written informed consent was obtained
prior to interviews from each adult caretaker during base-
line data collection. All caretakers approached provided
informed consent for the study, except 18 who refused to
have a blood sample taken from their children.
3. Results
A total of 544 names of eligible children were identi-
ﬁed at the health facilities, 467 of whom were found on
Day 7 and their caretakers interviewed; 77 (14.2%) of the
children were not included because they were not found
at home (70), they were >5 years of age (2), they did not
receive ALu (4) or they had died (1). Blood samples for
lumefantrine concentrations were collected on Day 7 from
446 children; blood samples could not be collected from
21 children because their caretakers refused (18), the RAs
failed to draw a second sample after the ﬁrst attempt failed
(2) or the capillary tube broke (1). Two caretakers could
not recall most of the information; therefore, analysis was
carried out based on the 444 children who  had complete
data.
Table 1 demonstrates no difference in sociodemo-
graphic characteristics between children who  adhered to
ALu treatment and those who did not. More than one-half
of the children (58.3%) were aged ≥2 years and over one-
half of the caretakers (57.9%) had at least primary level
education.
The level of reported adherence to ALu was high
(392/444; 88.3%). Figure 2 shows that the number of
Figure 2. Reported percent adherence rate by caretakers for each of the
six  doses and cumulative adherence from the ﬁrst to sixth dose (n = 444).
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Table 2
Logistic regression analysis of factors inﬂuencing adherence to artemether/lumefantrine (ALu) among children under ﬁve in Kilosa District, Tanzania
(n  = 444)
Factor OR 95% CI Adjusted OR 95% CI
Access to healthcare services
Child’s age ≥2 years 1.47 0.82–2.61 1.80 0.90–3.58
Married 1.74 0.95–3.19 1.87 0.90–3.88
Caretaker’s basic education ≥7 years 1.32 0.74–2.35
Residing in semi-urban area 1.32 0.67–2.60
Using own  or hired bicycle to go to health facility 1.16 0.58–2.29
Distance <5 km from a government facility 1.46 0.81–2.63
Knowledge on malaria
Knowledge that mosquitoes cause malaria 1.65 0.65–4.17
Knowledge that high fever causes convulsion in children 1.41 0.76–2.60
Knowledge of treatment of severe malaria 0.45 0.20–1.01
Knowledge that dawa mseto (ALu) is the recommended drug for the
treatment of malaria ya kawaida (uncomplicated malaria)
0.73 0.39–1.37
Socioeconomic status
Less poor (quintiles 3–5) 2.45 1.35–4.45 2.23 1.20–4.13
Other  factors
History of vomiting during malaria episode 0.68 0.22–2.06
Taken food with oil 4.62 2.53–8.41 4.60 2.49–8.50
Taken  adequate amount of food 1.08 0.59–1.98
Sought treatment same or next day 0.97 0.51–1.85
OR: odds ratio.
children who were reported to have taken all doses, in time,
was lowest for the last two doses.
When controlling for other factors, children from less
poor households were more likely to report adherence to
ALu treatment compared with the poor (OR = 2.45, 95% CI
1.35–4.45; adjusted OR = 2.23, 95% CI = 1.20–4.13) (Table 2).
Children who took food with oil were also more likely
to adhere to ALu treatment compared with those who
did not (OR = 4.62, 95% CI 2.53–8.41; adjusted OR = 4.60,
95% CI 2.49–8.50). Caretakers from the third SES quintile
were most likely to adhere to treatment compared with
the ﬁrst quintile, however there was no observed trend.
Although the majority of caretakers (409/444; 92.1%)
reported being advised on the frequency and duration for
ALu administration, the knowledge did not signiﬁcantly
inﬂuence the reported adherence. Basic education, offered
for 7 years in the country, did not inﬂuence adherence to
the treatment schedule.
No signiﬁcant difference in mean blood lumefantrine
concentrations was found between children whose
caretakers reported adherence and those who reported
non-adherence. The corresponding median levels were
286 nmol/l and 261 nmol/l, respectively (Figure 3). How-
ever, there was a wide variation in blood lumefantrine con-
centrations, ranging from 25 nmol/l (LoQ) to 9318 nmol/l
for the total group, and from 25 nmol/l to 1382 nmol/l for
those with reported non-adherence and from 25 nmol/l to
9318 nmol/l for those with reported adherence. Extreme
values (outliers) are not shown in Figure 3.
4. Discussion
This study has shown a high (88%) level of reported
adherence to ALu treatment under real-life settings, con-
trary to fears that efﬁcacy observed in controlled trials
might not be reﬂected in real-life situations.22 Similar ﬁnd-
ings were reported in studies performed in Kilombero/
Ulanga Districts and in Zanzibar Islands, Tanzania, despite
some methodological differences. Whereas these stud-
ies included patients residing closer to health facilities
(5–6 km from health facilities), mostly in urban and semi-
urban areas and applied presumptive malaria diagnosis,9
the current included children from rural remote areas
(up to 25 km away) where the burden of malaria is the
highest.23
Therefore, the current study conﬁrms a high adher-
ence to ALu among under ﬁves diagnosed to have malaria
using a RDT even in most rural settings remote from health
facilities.
No signiﬁcant difference in blood lumefantrine concen-
trations was found between children reported to adhere
to therapy and those who did not, in line with a study
in Malawi24 but contrary to a study in Uganda.6 One of
the reasons for the lack of any difference might be due
to the lack of a clear cut-off point.24 Although a previ-
ous study in Thailand reported a Day 7 blood lumefantrine
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Figure 3. Distribution of lumefantrine blood concentration levels of study
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box plot.
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concentration cut-off point of 331 nmol/l (175 ng/ml),25
another study in Malawi reported patients were cured
even below this level.24 The difference might be explained
by possible variations in food intake,26 as the levels of
lumefantrine blood concentrations may  increase 16-fold
in patients who took the drug with fatty food com-
pared with without fat.27,28 Age-based dosage schedules
of ALu might also explain the unpredictable blood con-
centrations of lumefantrine, since the dose per kg may
vary widely between patients, as reported for the CQ/SP
combination.29 This underscores the need to monitor the
rate of adherence to treatment guidelines by providers
as well as treatment schedules among patients in rural
areas when implementing ALu treatment on a wide scale in
Africa.
The high reported adherence found in this study can be
explained by the availability of ALu in pre-packaged pack-
ets with pictorial instructions, which have been reported to
improve caretakers’ understanding of the schedule admin-
istration of the drug30 and hence they are more likely
to follow the provider’s advice.12,22,31 Studies conducted
when CQ resistance was high reported low adherence
levels,10,11 thus the highly efﬁcacious ALu used in the
present study might also explain the high reported level
of adherence to treatment.22
Non-adherence to ALu treatment found in this study
was mostly attributed to untimely dosing rather than
missing doses, contrary to concerns that caretakers might
discontinue treatment and save the remaining drugs for
later use.1,2 The high level of non-adherence in the last
two doses has also been reported in previous studies in
Tanzania and Malawi.8,24 This might be due to some care-
takers perceiving that a child playing after an initial dose
is cured.16 Encouragingly, the low non-adherence level
might have little impact on the treatment strategy; how-
ever, there is a potential risk of building up pressure for
resistant strains over time.32
Children from the less poor households were found
to adhere to treatment better than poor patients. This
can partly be explained by the higher level of educa-
tion among caretakers in the less poor households and
the tendency to own radios compared with the poor.9
This might have exposed them to more information
disseminated by the National Malaria Control Pro-
gramme  through radios and posters since the introduction
of ALu.
4.1. Methodological issues
Caretakers’ reports are subjective and were likely to
overestimate the level of reported adherence owing to pos-
sibilities of obtaining socially desirable responses.24 This
was minimised by explaining to the caretaker the objec-
tive of the study prior to the interviews. The fact that most
children were no longer sick on Day 7 reduced the likeli-
hood of receiving desirable responses. This is in contrast
to reports of limited validity of caretakers’ reports when
interviewed at the health facilities.33 Pill count could not
be performed on Day 7 since most of the caretakers had
lost the packets. This limited the opportunity to triangulate
study ﬁndings. However, the fact that the results conform
to other community-based studies conducted in Tanzania
where pill count was  performed indicates that misreport-
ing might be minimal.
Recalling detailed information about how the drug was
administered after 7 days might result in data inaccuracy
as some details might be forgotten. We tried to minimise
this by following-up children weekly when the caretakers
could still remember the details. In addition, a sick child
tends to draw the attention of caretakers in a household,
thus increasing the likelihood of remembering events in
more details.
Blood lumefantrine concentrations would be useful
when studying adherence. However, the lack of a clear cut-
off point24 and baseline levels limited a detailed analysis.
There were also other challenges resulting from applying
the method in a real-life situation. Several methodolog-
ical issues were found in this study that could limit
the usefulness of the capillary blood sampling method
for lumefantrine in evaluating ALu effectiveness under
real-life conditions. These included the lack of base-
line lumefantrine concentration, inability to control or
record food intake, and inconsistency in determining ALu
dosage where some prescribers based the dosage on child
weight while others used age. In addition, some pre-
scribers used child weight measured on the same day
while others used the record found in the growth moni-
toring card, which could be outdated by several weeks or
months.
5. Conclusion
This study showed that the reported rate of adher-
ence to ALu treatment was encouragingly high in rural
villages with or without a health facility. The large vari-
ability in lumefantrine concentrations cast doubt on the
rationale of using aged-based dosage schedules of ALu
as presently used in some facilities in Tanzania. Non-
adherence was  mainly attributed to off-schedule dosing
rather than taking a fewer number of doses and was
more pronounced in the last two  doses. Despite the high
adherence, advocacy is still needed to improve caretakers’
understanding of the importance of adhering to the dose
schedule in order to reduce the risk of building up resistant
strains.
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